m+Medelevator.RU
← Поиск публикаций
Bioactive materials · 2025

Plant-derived vesicle-like nanoparticles for immunomodulation: Mechanisms and applications.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Wang Simin, Zhang Yanli, Zeng Yuting, Luo Xin, Chen Jiaping, Deng Qianwen, Xiao Ping, Lin Ruofei, Chen Xiuwen, Ding Xian, Li Qianlin, Qiu Sijie, Yang Dehong, Yan Wenjuan

Аннотация

Immune dysregulation can result in sustained activation of the immune system, leading to systemic chronic inflammation. This condition significantly disrupts immune homeostasis and is intimately associated with the onset of numerous chronic systemic diseases. Currently, the treatment of diseases related to immune dysregulation confronts several challenges, most notably the substantial side effects and inconsistent efficacy of long-term immunosuppressive drug use. Consequently, developing immunomodulatory strategies that balance efficacy and safety has emerged as a prominent research focus. Plant-derived vesicle-like nanoparticles (PVLNs), natural nanomaterials secreted by plant cells, exhibit significant potential in immunomodulation owing to their excellent biocompatibility, minimal immunogenicity, and cross-species communication capabilities. This paper reviews the biogenesis, composition, and properties of PVLNs, emphasizing the mechanisms of innate and adaptive immunomodulation they mediate and their applications in diseases characterized by immune disorders. It also analyzes the challenges related to target delivery, stability optimization, drug loading, and storage encountered in their engineering. In the future, as the mechanisms of PVLNs are more deeply understood and nanotechnology continues to advance, their potential in precision immunotherapy and clinical translation is anticipated to be further augmented.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты